Antibiotics have been hailed by many as "miracle drugs" that have been effectively treating infectious diseases for over a century, leading to a marked reduction in morbidity and mortality. However, with the increasing use of antibiotics, we are now faced not only with the increasing threat of antibiotic resistance, but also with a rising concern about potential long-term effects of antibiotics on human health, including the development of obesity. The obesity pandemic continues to increase, a problem that affects both adults and children alike. Disruptions to the gut microbiome have been linked to a multitude of adverse conditions, including obesity, type 2 diabetes, inflammatory bowel diseases, anxiety, autism, allergies, and autoimmune diseases. This review focuses on the association between antibiotics and obesity, and the role of the gut microbiome.
evidence that the gut microbiome has a range of effects on the host's physiological processes and behaviour. [16] [17] [18] [19] Dysbiosis (imbalance in gut microbiota) has been linked to the development of obesity by multiple mechanisms, via either direct effects on the gut or indirect regulation of distal organs 17, 20 ( Figure 1 ). These bacteria are able to break down indigestible polysaccharides (fibre) to short-chain fatty acids (SCFAs), which provide 80-200 kcal/d of energy to normal adults. 16 Dysbiosis (eg, a 20% increase in Firmicutes and a corresponding 20% decrease in Bacteroidetes) can result in an additional 150 kcal of energy harvested per day. 11, 19 SCFAs also modulate the secretion of gut hormones (glucagon-like peptide and peptide YY), both of which directly influence satiety 18 ( Figure 1 ).
In addition, the gut bacteria have an effect on bile acid metabolism, leading to a reduction in the number of bacteria considered to be protective against obesity 21 ( Figure 1 ). Bile acids acting as ligands of the nuclear farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (TGR5) are postulated to be involved in the regulation of gut hormone secretion, as well as in glucose and lipid metabolism [22] [23] [24] [25] ( Figure 1 ).
The gut microbiome also has the ability to disrupt the gut mucosal barrier leading to increased exposure of the host's immune system to bacterial products 16, 18 ( Figure 1 ). Increases in certain bacteria, and consequently on the concentration of their membrane lipopolysaccharides (LPS), have been proposed to lead to a condition known as metabolic endotoxaemia. 18, 26 Endotoxaemia along with increased gut permeability is associated with greater inflammation, which in turn leads to weight gain, fasting hyperglycaemia and hyperinsulinaemia 16, 18, 26 ( Figure 1 ). Dysbiosis also reduces the production of angiopoietin-like protein 4 (ANGPTL4) that inhibits lipoprotein lipase, leading to excess deposition of triglycerides in the adipose tissue, liver, pancreas and heart 27 ( Figure 1 ). Other metabolic effects of the gut bacteria are caused by changes in behaviour, including appetite modulation, food intake 18 and energy expenditure 11 ( Figure 1 ).
The published evidence linking gut microbiome to obesity is summarized in Table 1 . Most of what is known about this relationship comes from intervention studies in mice. [28] [29] [30] [31] One study by Backhed et al 28 in 2004 noted that conventionally raised mice had significantly more body fat compared with mice raised under germ-free conditions. Introduction of bacteria from the caecum of conventionally raised mice to the germ-free ones produced a 60% increase in body fat within 2 weeks despite reduced food intake 28 (Table 1 ). They also demonstrated that upon colonization of germ-free mice with the gut bacteria from conventionally raised mice, fasting leptin, glucose and insulin levels were increased leading to increasing body fat content.
Further, the ANGPTL4 levels were suppressed in the gut epithelium leading to elevated lipoprotein lipase activity, resulting in increasing triglyceride storage in adipocytes 28 (Table 1 ). In 2006, Turnbaugh et al 31 showed that transferring gut bacteria from obese mice to germ-free ones led to increased fat mass in the recipients (Table 1) .
Turnbaugh et al 32 further demonstrated that transplanting obesogenic gut microbiome to germ-free mice resulted in nearly a threefold increase in fat mass compared to mice who received gut microbiome from lean donors (Table 1) .
More recently, Ridaura et al 33 evaluated the effects of an obesogenic gut microbiome transfer from human donors to mouse recipients (Table 1 ). In contrast to earlier studies in mouse donors and recipients, they demonstrated that introduction of faecal microbiota from an overweight adult twin to normal weight germ-free mice resulted in a rapid weight gain in the mice. However, mice treated with faecal microbiota from the lean twin maintained their normal weight 33 (Table 1) . Further, compelling evidence of the effect of the gut microbiome on obesity comes from a study on gut microbiome transfer from human donors post bariatric surgery to mouse recipients, which promoted a reduction in fat deposition in recipient mice 34 (Table 1) Transplantation of gut microbiota from women 9.4-y post bariatric surgery or women who did not have any surgery to germ-free mice ↓ fat deposition by 43% in mice transplanted with microbiota post-RYGB and by 26% post-VBG compared with mice colonized with microbiota from women with no surgery Bariatric surgery seems to alter gut microbiome that are involved in metabolism and regulation of adiposity
thetaiotaomicron (glutamate-fermenting bacteria) in their gut, with an associated increase in serum glutamate concentrations ( Table 1) .
Transfer of B. thetaiotaomicron led to a reduction in serum glutamate levels, significantly reducing total fat mass and increasing lean body mass in mice on normal diet, and preventing further weight gain and adiposity in mice on a high-fat diet 35 (Table 1) . Bariatric surgery was also reported to alter the gut microbiome by increasing B. thetaiotaomicron numbers. 35 As a result, there was an associated reduction in serum glutamate levels and improvement in metabolic parameters including insulin resistance 35 (Table 1) .
Studies on the composition of the gut microbiome have shown that there is a difference between the bacterial taxa in lean and obese individuals. [36] [37] [38] [39] [40] There is, however, a paucity of human intervention studies to determine whether the gut microbiome does in fact influence body weight or whether previous observations were merely associations without a causal link. Dietary-intervention studies reveal that restrictive diets seem to result in a reduction of gut microbiota diversity and butyrate producers (Firmicutes, Lactobacillus spp., and Bifidobacterium spp.), which is associated with macronutrient deficiency rather than weight loss. 41, 42 Data from bariatric surgery indicate that a similar reduction in butyrate producers was also observed, depending on the surgical technique used. 43 This may result in reduction of energy harvested from food and SCFAs leading to reduction in gluconeogenesis and lipogenesis. 43 Studies on the use of probiotics as gut microbiota interventions have yielded conflicting results, but generally showed a reduction in body fat [44] [45] [46] [47] [48] (Table 1) . Further, studies on prebiotics indicate that these compounds are able to promote changes in both composition and function of the gut microbiota. [49] [50] [51] They increase the number of Bifidobacterium spp. and other butyrate producers, leading to improvements in metabolic outcomes and the gut barrier against pathogens. 52 However, prebiotic intervention is affected by the individual's gut microbiota composition and fibre intake. 53 Nicolucci et al 54 recently demonstrated in a randomized placebo-controlled trial that the prebiotic oligofructose-enriched inulin altered the gut microbiota in children (mainly increasing Bifidobacterium spp. and decreasing Bacteroides vulgatus numbers), leading to a reduction in weight and adiposity, as well as improving systemic inflammation and lipid metabolism (Table 1) .
Gut microbiome transfer is an effective treatment for Clostridium difficile infection. 55, 56 However, Alang and Kelly 57 report an interesting case where a female patient with recurrent C. difficile infection developed obesity following gut microbiome transfer (Table 1) . Of note, it was reported that she had not lost any weight as a result of the infection, but developed new-onset obesity after receiving gut microbiome from a healthy but similarly overweight donor. This weight gain was T A B L E 1 (Continued)
| DO ANTIBIOTICS LEAD TO LONG-TERM ALTERATIONS IN THE GUT MICROBIOME?
Recent studies in adults (using 16S rRNA gene sequencing) have
shown that antibiotics are able to alter the intestinal microbiome in the short term by reducing the diversity of bacterial taxa. [59] [60] [61] [62] [63] [64] The long-term effects of antibiotics on gut microbial composition have been more variable, with studies reporting differences in both interand intra-individual responses to the same antibiotic.
62,65
Although there is a high prevalence of antibiotic use in children,
there are very few studies looking into their effect on the developing gut microbiome. A recent longitudinal study of the gut microbiome in 39 children showed fairly similar findings as in adults. 66 This study analysed stool samples of children that had been exposed or unexposed to multiple courses of antibiotics within the first 3 years of life. Using both 16S rRNA gene and metagenomics sequencing, it was reported that there was less microbial diversity in terms of bacterial species and strains at 3 years of age in the children exposed to antibiotics. 66 However, there were apparent flaws in the studies published so far, as the number of subjects were small and had significant demographic heterogeneity. 63, 67 The type of antibiotic used, its route of administration, and the subject's age at the time of administration seem to influence the effects on the gut microbiome. 64, 68, 69 In addition, diet, lifestyle, other medications and products such as probiotics further complicate this conundrum. Since the 1950s, antibiotics have been added to food and water in pigs, cows and chickens as an effective method to enhance growth, especially weight gain. 73 This practice has been widely adopted by farmers, and a number of different antibiotics have been used for this purpose. [74] [75] [76] Notably, early-life exposure to antibiotics in these animals has far greater effects on weight gain and feed efficiency than if exposure occurred in later life. (Table 2 ). Male mice whose mother were treated with penicillin before birth and throughout weaning exhibited markedly increased total mass and fat mass. 15 In contrast, both male mice receiving antibiotics after weaning and female mice receiving antibiotics before birth and after weaning had similar body composition when compared with controls 15 ( Table 2 ). The authors also reported that low doses of antibiotics enhanced the effects of a high-fat diet on the development of obesity in these mice. 15 Additionally, the study examined possible obesogenic effects of antibiotic-induced alterations in the gut microbiome. Caecal microbiota was transferred from 18-week-old control and penicillin-treated mice to 3-week-old germ-free mice, and those that received the penicillin-altered microbiota were heavier and had greater fat mass compared with controls 15 (Table 2) .
There have been a number of studies that aimed to assess whether the use of antibiotics may lead to obesity in humans, which are summarized in Table 2 . In adults, small observational studies reported that subjects treated with either broad-or narrow-spectrum antibiotics were more likely to gain weight compared with those who were not treated. (Table 2 ). There was also a slight increase in body weight of 1.3 kg and an acute but reversible increase in peptide YY secretion 81 ( Table 2 ). These effects might not be as pronounced compared with those of a longer antibiotic therapy, but a limitation of this study was the lack of a control (placebo) group.
In children, the evidence linking antibiotics usage to development of obesity has been inconsistent ( Table 2) . Prophylactic antibiotic treatment in children with cystic fibrosis was shown to result in weight gain 82 (Table 2) . Data from 10 randomized controlled trials indicated that antibiotic use in prepubertal children from low-and middleincome countries leads to increased growth, particularly weight gain 83 (Table 2) . However, these studies have only examined children with ongoing infections, whose resolution with antibiotic therapy might have been the underlying cause of weight gain, rather than the possible alterations in the gut microbiota.
Seven recent epidemiological studies in healthy children have provided evidence that the use of antibiotics is associated with obesity [84] [85] [86] [87] [88] [89] [90] (Table 2 ). These studies reported that antibiotic exposure in early life was linked to increased BMI and a greater prevalence of obesity among healthy children. [84] [85] [86] [87] [88] [89] [90] This effect was more marked in children who were as follows: (i) treated within the first 6 months of life; (ii) exposed to 3 or more courses of antibiotics; (iii) treated with broad-spectrum antibiotics; and (iv) males [84] [85] [86] [87] [88] 90 (Table 2) . Notably, the available evidence indicates that the associations of both gut microbiome and antibiotic usage with childhood obesity are often sexually dimorphic. These studies have shown that the adverse effects seen in males are not often mirrored in females. This is not particularly surprising as sexual dimorphism in association with environmental stressors early in life has been well described in the literature, 91 T A B L E 2 Existing evidence for a link between antibiotic exposure and obesity find that early-life antibiotics exposure significantly increases risk of childhood obesity (Table 2) . Unfortunately, as all these studies were observational in design, it is difficult to pinpoint antibiotic usage as the primary cause of obesity without considering other confounding factors, such as host genetics, dietary changes, maternal BMI, breastfeeding, maternal smoking and the infection itself. 84, 85, 88, 89, 94 Some of the data in these studies were also potentially unreliable as they were based on recall of antibiotics usage, and compliance with the prescribed antibiotic therapy was never reported. 84, 87, 89, 95 In contrast, 2 studies in 2016 suggest that there was no evidence that antibiotics had an effect on weight gain or on the development of obesity in children. 95, 96 The first study showed no effects of prolonged antibiotic prophylaxis (trimethoprim-sulfamethoxazole) for 2 years on weight gain in children with recurrent urinary tract infection 96 ( Table 2 ). However, this study used a single class of antibiotics as prophylaxis, so that the results might have been affected by the type and dose of antibiotics used. Gerber et al 95 reported on a large retrospective longitudinal study of nearly 39 000 children, finding that antibiotic exposure within the first 6 months of life did not affect weight gain between 2 and 5 years of age (Table 2) . Nonetheless, as with other previous studies, there was inadequate information regarding antibiotic exposure and compliance with the prescribed therapy.
| DOES INFECTION CAUSE OBESITY?
Alternatively, infection rather than antibiotics could be the contributing factor to the development of obesity. A large study on over 260 000 individuals reported an association between infection and increased odds of obesity in childhood and adolescence, which was independent of antibiotic treatment 94 (Table 2) . Further, the odds of obesity were also higher in the group with untreated infections than among those who were both uninfected and untreated (Table 2) . A limitation in that study was that the assessment of obesity was made by comparing BMI among children across a wide age range (from 2 to 18 years), and comparisons between children of similar age might have yielded different results.
If infection is said to cause obesity, should we also consider viruses and other pathogenic organisms apart from bacteria as causative agents for obesity? This concept "infectobesity" is not new and has been studied in animal models for the past 2 decades. 97 At least ten different viruses have been reported to cause obesity in animals, including canine distemper virus, SMAM-1 avian adenovirus and human adenoviruses Ad36 and Ad37. 98 Further, SMAM-1 and Ad36 in particular have been found to be associated with obesity in humans. 97, 98 However, beyond associations, the role of these viruses in the development of obesity in humans remains unclear. T A B L E 2 (Continued)
| CONCLUSION
There are strong data supporting the role of antibiotics in the development of obesity in well-controlled animal models, but evidence in humans remains inconclusive. Association studies suggest young children may be particularly vulnerable to the weight-promoting effects of recurrent courses of antibiotics through alterations in the gut microbiome. Randomized controlled trials could clarify the effects of long-term antibiotic treatment on weight gain. However, it would be unethical to conduct such studies, and we will need to rely on trials of antibiotic exposure in children where weight gain is a secondary outcome. These studies would help us better understand the role of antibiotics in the ongoing obesity epidemic.
